scispace - formally typeset
M

Maria Romano

Researcher at University of Naples Federico II

Publications -  194
Citations -  3429

Maria Romano is an academic researcher from University of Naples Federico II. The author has contributed to research in topics: Apoptosis & Melanoma. The author has an hindex of 29, co-authored 188 publications receiving 2880 citations. Previous affiliations of Maria Romano include Magna Græcia University.

Papers
More filters
Journal ArticleDOI

Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: The challenge ahead

William H. Goodson, +180 more
- 01 Jun 2015 - 
TL;DR: Low-dose exposures to common environmental chemicals that are deemed safe individually may be combining to instigate carcinogenesis, thereby contributing to the incidence of cancer.
Journal ArticleDOI

Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells.

TL;DR: Rapamycin targets 2 pathways that are crucial for cell survival and chemoresistance of malignant lymphoblasts--PI3k/Akt through the mammalian target of rapamycin and NF-kappaB through FKBP51--suggesting that the drug could be beneficial in the treatment of childhood ALL.
Journal ArticleDOI

Rapamycin inhibits doxorubicin-induced NF-κB/Rel nuclear activity and enhances the apoptosis of melanoma cells

TL;DR: It is found that rapamycin sensitised a human melanoma cell line, established from a patient, to the cytolytic effects of doxorubicin, suggesting that the macrolide agent could synergise with NF-kappaB-inducing anti-cancer drugs in PTEN-positive tumours.
Journal ArticleDOI

Relevance of motion artifact in electromyography recordings during vibration treatment

TL;DR: The data presented in this study emphasize the need for the removal of motion artifacts, as they consistently affect RMS estimation, which is often used as a concise muscle activity index during vibrations.
Journal ArticleDOI

A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma.

TL;DR: It is suggested that FKBP51s is a potential target of immunomodulatory strategies for glioblastoma treatment after addressing the mechanism of post-translational regulation of PD-L1 protein in glioma.